Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Pipeline Insight, 2020

  • RnM3882149
  • |
  • 14 February, 2020
  • |
  • 106 Pages
  • |
  • DelveInsight
  • |
  • Pharma & Healthcare

Check Discount on this report



Purchase this Report

$2,500.00
$5,000.00
$7,500.00
1,980.00
3,960.00
5,940.00
2,310.00
4,620.00
6,930.00
378,225.00
756,450.00
1,134,675.00
208,425.00
416,850.00
625,275.00
Credit card Logo